This article is more than 5 years old. Information may no longer be current.
PolyActiva completes enrollment in glaucoma implant trial
Click Here to Manage Email Alerts
Patient enrollment in a phase 1 clinical trial of PolyActiva’s biodegradable, slow-release ocular implant for the treatment of glaucoma has been completed, the company announced in a press release.
The study is evaluating the safety and tolerability of the Latanoprost FA SR implant, which is designed to provide a constant daily dose of latanoprost free acid for at least 30 weeks.
“To date, our phase 1 study has demonstrated that our implant is safe and well tolerated and provides treatment for a 6-month period before it biodegrades completely. We have achieved a major step forward in the advance of ocular implants developing the first implant to completely disappear within 6 weeks of the completion of treatment” PolyActiva CEO Russell Tait, PhD, said in the release. “With recruitment now closed, top-line safety and initial efficacy data from this study will be available by the end of this calendar year.”
The company also announced that it has closed $7 million to fund the next clinical study, which will focus on the efficacious dose of the glaucoma implant, and the first clinical study of an ocular implant to prevent endophthalmitis after cataract surgery.